Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sopherion Therapeutics Inc., Zeneus deal

Sopherion licensed from Zeneus exclusive North American development and commercialization rights to Myocet liposomal doxorubicin.

Read the full 153 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE